Enzyme Replacement Therapy Companies, Corporate Milestones, Corporate Growth and Development Strategy, Mergers and Acquisitions (M&A)

Enzyme Replacement Therapy Companies and Competitive Landscape

The global enzyme replacement therapy market size is calculated at USD 10.4 billion in 2024, grew to USD 11.34 billion in 2025, and is projected to reach around USD 24.71 billion by 2034. The market is expanding at a CAGR of 9.04% between 2025 and 2034.

Top Companies in the Enzyme Replacement Therapy

• AbbVie
• Alexion Pharmaceuticals, Inc.
• Amicus Therapeutics
• AstraZeneca plc
• Biomarin Pharmaceutical, Inc.
• Denali Therapeutics, Inc.
• GC Biopharma
• Genzyme Corporation
• Novel Pharma
• Pfizer, Inc.
• Protalix BioTherapeutics, Inc.
• Sanofi
• Takeda Pharmaceuticals

Recent Developments in the Enzyme Replacement Therapy Market

• In November 2023, Takeda Pharmaceuticals received U.S. FDA approval for Adzynma, the first recombinant protein product, for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a life-threatening and rare blood clotting disorder.
• In May 2023, the European Commission approved market authorization for PRX-102 (pegunigalsidase alfa), the first PEGylated enzyme replacement therapy for Fabry disease. The therapy was developed by Chiesi Global Rare Diseases in collaboration with Protalix BioTherapeutics, Inc.

Enzyme Replacement Therapy Market: U.S. Shipment and Product Overview